TY  - JOUR
A1  - Kinzler, Maximilian Nikolai
A1  - Klasen, Christina
A1  - Schulze, Falko
A1  - Herrmann, Eva
A1  - Schnitzbauer, Andreas
A1  - Trojan, Jörg
A1  - Zeuzem, Stefan
A1  - Wild, Peter Johannes
A1  - Walter, Dirk
T1  - Impact of liver fibrosis on survival of patients with intrahepatic cholangiocarcinoma receiving gemcitabine-based chemotherapy
T2  - Journal of Clinical Medicine
N2  - Intrahepatic cholangiocarcinoma (iCCA) is the most frequent subtype of cholangiocarcinoma (CCA), and the incidence has globally increased in recent years. In contrast to surgically treated iCCA, data on the impact of fibrosis on survival in patients undergoing palliative chemotherapy are missing. We retrospectively analyzed the cases of 70 patients diagnosed with iCCA between 2007 and 2020 in our tertiary hospital. Histopathological assessment of fibrosis was performed by an expert hepatobiliary pathologist. Additionally, the fibrosis-4 score (FIB-4) was calculated as a non-invasive surrogate marker for liver fibrosis. For overall survival (OS) and progression-free survival (PFS), Kaplan–Meier curves and Cox-regression analyses were performed. Subgroup analyses revealed a median OS of 21 months (95% CI = 16.7–25.2 months) and 16 months (95% CI = 7.6–24.4 months) for low and high fibrosis, respectively (p = 0.152). In non-cirrhotic patients, the median OS was 21.8 months (95% CI = 17.1–26.4 months), compared with 9.5 months (95% CI = 4.6–14.3 months) in cirrhotic patients (p = 0.007). In conclusion, patients with iCCA and cirrhosis receiving palliative chemotherapy have decreased OS rates, while fibrosis has no significant impact on OS or PFS. These patients should not be prevented from state-of-the-art first-line chemotherapy.
KW  - chemotherapy
KW  - intrahepatic cholangiocarcinoma
KW  - liver fibrosis
KW  - overall survival
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/79889
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-798896
SN  - 2077-0383
VL  - 11
IS  - 7, art. 2057
SP  - 1
EP  - 10
PB  - MDPI
CY  - Basel
ER  -